Product Information
CEFEPIME HCL 2 GRAM VIAL is a generic product labeled by Sagent Pharmaceuticals, priced at $5.3480 per EA under NDC 25021012250. Its NADAC has been published 122 times since Jan 22, 2014.
FDA first approved this application on Mar 20, 2008. Its Orange Book therapeutic-equivalence code is AP.
Strength
2 g/1
Manufacturer
Sagent PharmaceuticalsNDC
25021012250
Classification
Generic
Dosage Form
INJECTION, POWDER, FOR SOLUTION
Route
INTRAVENOUS
Effective Date
3/19/2025
Active Ingredients
CEFEPIME HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA065441FDA Approved
3/20/2008
TE Code
AP
On Market Since
5/1/2008
Pharmacological Classes
Price Statistics
The NADAC for CEFEPIME HCL 2 GRAM VIAL has been published 122 times since Jan 22, 2014, and over the history we have for it it has declined 32.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.3480 per EA |
|---|---|
| All-time high | $7.9605 (Dec 16, 2015) |
| All-time low | $5.3480 (Mar 19, 2025) |
| Median price | $7.9065 |
| Average price | $7.4932 |
| Largest weekly change | -30.1% (Nov 20, 2024) |
| Weeks tracked | 122 |
| Tracking since | Jan 22, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
-32.8%
5Y
-32.8%
All
-32.4%
Last surveyed Apr 16, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the cefepime hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sagent Pharmaceuticals manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
cefepime hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cephalosporin Antibacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CEFEPIME HCL 2 GRAM VIAL?
The current National Average Drug Acquisition Cost (NADAC) for CEFEPIME HCL 2 GRAM VIAL, manufactured by Sagent Pharmaceuticals, is $5.3480 per EA (NDC 25021012250), effective Apr 16, 2025.
How has the price of CEFEPIME HCL 2 GRAM VIAL changed over time?
Over the history we have for it, the NADAC for CEFEPIME HCL 2 GRAM VIAL has declined 32.4%. It has been tracked across 122 weekly CMS publications since Jan 22, 2014.
What are the highest and lowest recorded NADAC prices for CEFEPIME HCL 2 GRAM VIAL?
Since Jan 22, 2014, the NADAC for CEFEPIME HCL 2 GRAM VIAL has ranged from a low of $5.3480 (Mar 19, 2025) to a high of $7.9605 (Dec 16, 2015), with a median of $7.9065 per EA.
Are there cheaper alternatives to CEFEPIME HCL 2 GRAM VIAL?
No other NADAC-published product currently shares the active ingredient and strength of CEFEPIME HCL 2 GRAM VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CEFEPIME HCL 2 GRAM VIAL?
CEFEPIME HCL 2 GRAM VIAL (NDC 25021012250) is labeled by Sagent Pharmaceuticals, and CMS classifies it as a generic product.